OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 175.6 Million SEK | 21.47% |
| 2022 | 135.62 Million SEK | 22.69% |
| 2021 | 110.54 Million SEK | 10.61% |
| 2020 | 99.93 Million SEK | 7.13% |
| 2019 | 93.28 Million SEK | 43.51% |
| 2018 | 65 Million SEK | 18.92% |
| 2017 | 54.66 Million SEK | 1822133433.33% |
| 2016 | -3.00 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 25.01 Million SEK | -51.14% |
| 2024 Q2 | 42.15 Million SEK | 71.85% |
| 2023 Q4 | 51.2 Million SEK | 18.7% |
| 2023 FY | 164.74 Million SEK | 21.47% |
| 2023 Q1 | 41.81 Million SEK | 2.53% |
| 2023 Q2 | 40.89 Million SEK | -2.19% |
| 2023 Q3 | 43.14 Million SEK | 5.5% |
| 2022 Q3 | 32.58 Million SEK | -2.63% |
| 2022 Q2 | 33.46 Million SEK | 16.24% |
| 2022 FY | 135.62 Million SEK | 22.69% |
| 2022 Q4 | 40.77 Million SEK | 25.14% |
| 2022 Q1 | 28.79 Million SEK | -4.22% |
| 2021 FY | 110.54 Million SEK | 10.61% |
| 2021 Q4 | 30.06 Million SEK | 27.98% |
| 2021 Q3 | 23.48 Million SEK | -22.05% |
| 2021 Q2 | 30.13 Million SEK | 12.17% |
| 2021 Q1 | 26.86 Million SEK | -6.43% |
| 2020 Q4 | 28.7 Million SEK | 23.12% |
| 2020 Q3 | 23.31 Million SEK | -4.26% |
| 2020 FY | 99.93 Million SEK | 7.13% |
| 2020 Q1 | 23.55 Million SEK | -24.88% |
| 2020 Q2 | 24.35 Million SEK | 3.41% |
| 2019 Q1 | 19.38 Million SEK | -6.34% |
| 2019 FY | 93.28 Million SEK | 43.51% |
| 2019 Q4 | 31.35 Million SEK | 38.89% |
| 2019 Q3 | 22.57 Million SEK | 13.04% |
| 2019 Q2 | 19.97 Million SEK | 3.0% |
| 2018 Q3 | 15.31 Million SEK | 6.98% |
| 2018 Q2 | 14.31 Million SEK | -1.99% |
| 2018 Q1 | 14.6 Million SEK | 0.0% |
| 2018 FY | 65 Million SEK | 18.92% |
| 2018 Q4 | 20.7 Million SEK | 35.15% |
| 2017 FY | 54.66 Million SEK | 1822133433.33% |
| 2016 FY | -3.00 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -111.951% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 71.298% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 71.298% |
| Arcoma AB | 53.25 Million SEK | -229.755% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -3433.93% |
| BICO Group AB (publ) | 2.84 Billion SEK | 93.835% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 16.557% |
| CellaVision AB (publ) | 295.99 Million SEK | 40.673% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -154.753% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -13313.022% |
| C-Rad AB (publ) | 3.8 Million SEK | -4521.079% |
| Duearity AB (publ) | 21.58 Million SEK | -713.533% |
| Dignitana AB (publ) | 74.73 Million SEK | -134.962% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -6403.741% |
| Getinge AB (publ) | 10.75 Billion SEK | 98.368% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -863.329% |
| Iconovo AB (publ) | 63.35 Million SEK | -177.172% |
| Integrum AB (publ) | 90.57 Million SEK | -93.881% |
| Luxbright AB (publ) | 23.09 Million SEK | -660.49% |
| Mentice AB (publ) | 237.06 Million SEK | 25.926% |
| Paxman AB (publ) | 133.8 Million SEK | -31.241% |
| Promimic AB (publ) | 48.55 Million SEK | -261.676% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -8.139% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -150.945% |
| ScandiDos AB (publ) | 61.03 Million SEK | -187.691% |
| Sectra AB (publ) | 39.06 Million SEK | -349.533% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -0.615% |
| Senzime AB (publ) | 141.51 Million SEK | -24.085% |
| SpectraCure AB (publ) | 12.12 Million SEK | -1347.897% |
| Stille AB | 87.21 Million SEK | -101.333% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 96.846% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 60.174% |